Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial.

MLA

Nakao, Akira, et al. “Nab-Paclitaxel Maintenance Therapy Following Carboplatin + Nab-Paclitaxel Combination Therapy in Chemotherapy Naïve Patients with Advanced Non-Small Cell Lung Cancer: Multicenter, Open-Label, Single-Arm Phase II Trial.” Investigational New Drugs, vol. 36, no. 5, Oct. 2018, pp. 903–10. EBSCOhost, https://doi.org/10.1007/s10637-018-0617-6.

APA

Nakao, A., Uchino, J., Igata, F., On, R., Ikeda, T., Yatsugi, H., Hirano, R., Sasaki, T., Tanimura, K., Imabayashi, T., Tamiya, N., Kaneko, Y., Yamada, T., Nagata, N., Watanabe, K., Kishimoto, J., Takayama, K., & Fujita, M. (2018). Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial. Investigational New Drugs, 36(5), 903–910. https://doi.org/10.1007/s10637-018-0617-6

Chicago

Nakao, Akira, Junji Uchino, Fumiyasu Igata, Rintaro On, Takato Ikeda, Hiroshi Yatsugi, Ryosuke Hirano, et al. 2018. “Nab-Paclitaxel Maintenance Therapy Following Carboplatin + Nab-Paclitaxel Combination Therapy in Chemotherapy Naïve Patients with Advanced Non-Small Cell Lung Cancer: Multicenter, Open-Label, Single-Arm Phase II Trial.” Investigational New Drugs 36 (5): 903–10. doi:10.1007/s10637-018-0617-6.